Table 1. Patients' characteristics according to the highest grade of CIN developed during first-line chemotherapy.
| Features | All, n (%) | Absent (grade 0), n (%) | Moderate (grade 1–2), n (%) | Severe (grade 3–4), n (%) | P value | |
|---|---|---|---|---|---|---|
| CIN | 150 (100.0) | 30 (20.0) | 54 (36.0) | 66 (44.0) | ||
| Age (years) Median age: 52 y | ≤ median | 84 (56.0) | 17 (56.7) | 34 (63.0) | 33 (50.0) | 0.362 |
| > median | 66 (44.0) | 13 (43.3) | 20 (37.0) | 33 (50.0) | ||
| Sex | Male | 92 (61.3) | 21 (70.0) | 37 (68.5) | 34 (51.5) | 0.090 |
| Female | 58 (38.7) | 9 (30.0) | 17 (31.5) | 32 (48.5) | ||
| Differentiation grade | Low/undifferentiated | 98 (65.3) | 22 (73.3) | 30 (55.6) | 46 (69.7) | 0.309 |
| Moderate/high | 15 (10.0) | 1 (3.3) | 8 (14.8) | 6 (9.1) | ||
| Unclassified | 37 (24.7) | 7 (23.3) | 16 (29.6) | 14 (21.2) | ||
| Synchronous metastasis | Presence | 124 (82.7) | 27 (90.0) | 45 (83.3) | 52 (78.8) | 0.399 |
| Absent | 26 (17.3) | 3 (10.0) | 9 (16.7) | 14 (21.2) | ||
| Liver metastasis | No | 87 (58.0) | 14 (46.7) | 33 (61.1) | 40 (60.6) | 0.372 |
| Yes | 63 (42.0) | 16 (53.3) | 21 (38.9) | 26 (39.4) | ||
| Lung metastasis | No | 137 (91.3) | 27 (90.0) | 50 (92.6) | 60 (90.9) | 0.909 |
| Yes | 13 (8.7) | 3 (10.0) | 4 (7.4) | 6 (9.1) | ||
| Ascites and/or pleural effusion | No | 111 (74.0) | 23 (76.7) | 42 (77.8) | 46 (69.7) | 0.564 |
| Yes | 39 (26.0) | 7 (23.3) | 12 (22.2) | 20 (30.3) | ||
| Baseline hemoglobin Median Hb: 120 g/L | ≤ Median | 77 (51.3) | 11 (36.7) | 28 (51.9) | 38 (57.6) | 0.164 |
| > Median | 73 (48.7) | 19 (63.3) | 26 (48.1) | 28 (42.4) | ||
| Baseline platelet count Median count: 241 × 109/L | ≤ Median | 75 (50.0) | 11 (36.7) | 25 (46.3) | 39 (59.1) | 0.100 |
| > Median | 75 (50.0) | 19 (63.3) | 29 (53.7) | 27 (40.9) | ||
| No. of cycles of EOF5 administrated: median (range) | 6 (1–8) | 4 (1–7) | 6 (2–8) | 6 (2–8) | ||
| Relative dose-intensity: median | 0.90 | 0.93 | 0.90 | 0.89 | ||